Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous pr...

Full description

Bibliographic Details
Main Authors: Clara Esnault, David Schrama, Roland Houben, Serge Guyétant, Audrey Desgranges, Camille Martin, Patricia Berthon, Marie-Claude Viaud-Massuard, Antoine Touzé, Thibault Kervarrec, Mahtab Samimi
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
antibody–drug conjugates
oncodermatology
melanoma
skin squamous cell carcinoma
cutaneous T-cell lymphoma and Merkel cell carcinoma
Online Access:https://www.mdpi.com/2072-6694/14/3/778

Internet

https://www.mdpi.com/2072-6694/14/3/778

Similar Items